Phase II Trial of Dual LAG-3–PD-1 Inhibition With Neoadjuvant Relatlimab + Nivolumab in Resectable Stage III Melanoma

Dr Michael Davies highlights key studies presented at the 2022 Society for Melanoma Research Annual Congress in this commentary from Clinical Care Options (CCO)

Michael A. Davies, MD, PhD Released: November 17, 2022

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: November 14, 2022 Expired: November 13, 2023

Download slides on selected studies from the 2022 Society for Melanoma Research Annual Congress, as reported by Clinical Care Options (CCO)

Downloadable clinical resource with practical guidance on preventative care plans for transgender patients, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director Released: October 7, 2022